Source comparison
Sermorelin vs HGH: Treatment Comparison
Mechanism Stimulates pituitary GHRH receptors → pulsatile endogenous GH release Delivers bioidentical GH directly → steady-state hormone elevation Sermorelin preserves physiological feedback loops; HGH bypasses them entirely Regulatory Status Research peptide,
This comparison does not assign a generated winner or score.
- Mechanism
- Stimulates pituitary GHRH receptors → pulsatile endogenous GH release
- Delivers bioidentical GH directly → steady-state hormone elevation
- Sermorelin preserves physiological feedback loops; HGH bypasses them entirely
- Regulatory Status
- Research peptide, off-label prescribing permitted
- Schedule III controlled substance, FDA-approved for specific indications only
- HGH carries federal prescribing restrictions and enforcement risk for off-label use
- Typical Dosing
- 200–500 mcg subcutaneous once daily (bedtime)
- 0.1–0.3 mg/day subcutaneous (weight-based), titrated to IGF-1 levels
- Sermorelin dosing less precise due to individual pituitary variability
- Monthly Cost (Out-of-Pocket)
- $200–$400
- $800–$2,500
- Cost differential reflects manufacturing complexity and regulatory overhead
- Side Effect Profile
- Mild: injection site reactions, flushing, rare headache
- Moderate to severe: oedema, carpal tunnel syndrome, insulin resistance, joint pain
- Sermorelin's side effects are transient and dose-related; HGH's can be chronic and cumulative
- Professional Assessment
- Ideal for patients with residual pituitary function seeking physiological GH optimization without regulatory complexity
- Necessary for patients with organic pituitary failure or paediatric growth disorders; high efficacy but high cost and legal constraints